Den samlede observerede forekomst af ondartede svulster i det kliniske program med Xolair svarede til den forekomst, der blev rapporteret i den almindelige befolkning.
The overall observed incidence rate of malignancy in the Xolair clinical trial programme was comparable to that reported in the general population.